Efficacy of levodopa/benserazide dispersible tablet on the 'Delayed-ON' to first morning dose in patients with Parkinson's disease with motor fluctuations: a multicenter, randomized, open-label, cross-over trial.
Hee Jin Chang, Jongkyu Park, Sohee Oh, Chae Won Shin, Ji Won Kim, Jin Whan Cho, Jee-Young Lee
{"title":"Efficacy of levodopa/benserazide dispersible tablet on the 'Delayed-ON' to first morning dose in patients with Parkinson's disease with motor fluctuations: a multicenter, randomized, open-label, cross-over trial.","authors":"Hee Jin Chang, Jongkyu Park, Sohee Oh, Chae Won Shin, Ji Won Kim, Jin Whan Cho, Jee-Young Lee","doi":"10.14802/jmd.25031","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Delayed ON is a condition in which Parkinson's disease (PD) patients do not experience the effect of levodopa in time after taking the dosage. The efficacy of various oral levodopa regimens to overcome this problem has been investigated limitedly.</p><p><strong>Objective: </strong>To evaluate the efficacy of levodopa/benserazide dispersible tablet in PD patients with delayed ON to first morning dose.</p><p><strong>Methods: </strong>This multicenter, randomized, cross-over trial involved 40 eligible PD patients with delayed ON. Participants were randomized to receive either levodopa/benserazide 100mg dispersible or regular tablets for 4 weeks, thereafter one week wash-out interval, followed by an alternate drug for another 4-week. Participants took the investigational drug with the first-morning dose of their antiparkinsonian medications. Other medications were unchanged during the trial. The primary outcome was changes in time-to-ON after the first-morning dose recorded in a special diary before and after each therapy. We also evaluated changes in parkinsonism, motor fluctuations, and dyskinesia using the Unified PD Rating Scale and Unified Dyskinesia Rating Scale. Finally, we investigated whether the efficacy wase affected by Helicobacter pylori status using baseline serum samples from every participant.</p><p><strong>Results: </strong>Nine patients dropped out during the trial. The time-to-ON was significantly reduced by the dispersible tablet compared with the regular tablet (-34.72 vs -23.81 minutes, p=0.014). There were no significant changes in parkinsonian severity or dyskinesia with either drug. The dispersible formulation was beneficial for both Helicobacter pylori-positive and -negative groups.</p><p><strong>Conclusion: </strong>Levodopa/benserazide dispersible formulations can improve time-to-ON without exacerbating dyskinesia in PD patients suffering from delayed ON.</p>","PeriodicalId":16372,"journal":{"name":"Journal of Movement Disorders","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Movement Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14802/jmd.25031","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Delayed ON is a condition in which Parkinson's disease (PD) patients do not experience the effect of levodopa in time after taking the dosage. The efficacy of various oral levodopa regimens to overcome this problem has been investigated limitedly.
Objective: To evaluate the efficacy of levodopa/benserazide dispersible tablet in PD patients with delayed ON to first morning dose.
Methods: This multicenter, randomized, cross-over trial involved 40 eligible PD patients with delayed ON. Participants were randomized to receive either levodopa/benserazide 100mg dispersible or regular tablets for 4 weeks, thereafter one week wash-out interval, followed by an alternate drug for another 4-week. Participants took the investigational drug with the first-morning dose of their antiparkinsonian medications. Other medications were unchanged during the trial. The primary outcome was changes in time-to-ON after the first-morning dose recorded in a special diary before and after each therapy. We also evaluated changes in parkinsonism, motor fluctuations, and dyskinesia using the Unified PD Rating Scale and Unified Dyskinesia Rating Scale. Finally, we investigated whether the efficacy wase affected by Helicobacter pylori status using baseline serum samples from every participant.
Results: Nine patients dropped out during the trial. The time-to-ON was significantly reduced by the dispersible tablet compared with the regular tablet (-34.72 vs -23.81 minutes, p=0.014). There were no significant changes in parkinsonian severity or dyskinesia with either drug. The dispersible formulation was beneficial for both Helicobacter pylori-positive and -negative groups.
Conclusion: Levodopa/benserazide dispersible formulations can improve time-to-ON without exacerbating dyskinesia in PD patients suffering from delayed ON.
背景:迟发性ON是帕金森病(PD)患者服用左旋多巴后未及时体验到左旋多巴作用的一种情况。各种口服左旋多巴方案克服这一问题的有效性研究有限。目的:评价左旋多巴/苯塞拉肼分散片治疗PD患者延迟ON至晨服一次的疗效。方法:这项多中心、随机、交叉试验纳入了40例延迟性ON的PD患者。参与者随机接受左旋多巴/苯塞拉齐100mg分散片或常规片剂,为期4周,之后一周洗脱期,然后再服用替代药物4周。参与者在服用第一次早晨剂量的抗帕金森药物的同时服用研究药物。其他药物在试验期间没有变化。主要结果是在每次治疗前后记录在特殊日记中的第一个早晨剂量后的时间变化。我们还使用统一PD评定量表和统一运动障碍评定量表评估帕金森病、运动波动和运动障碍的变化。最后,我们使用每位参与者的基线血清样本来调查幽门螺杆菌状态是否会影响疗效。结果:9例患者在试验期间退出。与普通片剂相比,分散片的on时间显著缩短(-34.72 min vs -23.81 min, p=0.014)。两种药物对帕金森病的严重程度或运动障碍没有显著的改变。该分散制剂对幽门螺杆菌阳性组和阴性组均有益。结论:左旋多巴/苯塞拉肼分散制剂可改善PD延迟性ON患者的ON时间而不加重运动障碍。